Real-world use of sunitinib in Japanese patients with pancreatic neuroendocrine tumors: results from a post-marketing surveillance study

被引:0
作者
Kazuo Sato
Yasuharu Toyoshima
Shiho Moriyama
Yutaka Endo
Tetsuhide Ito
Emiko Ohki
机构
[1] Pfizer Japan,Fukuoka Sanno Hospital
[2] International University of Health and Welfare,undefined
来源
Cancer Chemotherapy and Pharmacology | 2019年 / 83卷
关键词
Pancreatic neuroendocrine tumors; Japan; Sunitinib; Safety; Objective response rate;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:201 / 207
页数:6
相关论文
共 181 条
[1]  
Hallet J(2015)Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes Cancer 121 589-597
[2]  
Law CH(2017)Cancer statistics, 2017 CA Cancer J Clin 67 7-30
[3]  
Cukier M(2008)One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States J Clin Oncol 26 3063-3072
[4]  
Saskin R(2015)Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis J Gastroenterol 50 58-64
[5]  
Liu N(2013)Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib Ther Adv Gastroenterol 6 396-411
[6]  
Singh S(2011)Sunitinib malate for the treatment of pancreatic neuroendocrine tumors N Engl J Med 364 501-513
[7]  
Siegel RL(2011)Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 514-523
[8]  
Miller KD(2012)Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial Jpn J Clin Oncol 42 903-911
[9]  
Jemal A(2013)Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor Invest New Drugs 31 1265-1274
[10]  
Yao JC(2015)Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan J Gastroenterol 50 769-775